Aventis Pharma: OPM disappointment continues… - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Aventis Pharma: OPM disappointment continues…

Oct 31, 2002

Aventis Pharma, has reported nearly 13% topline growth for 3QFY03 on the back of strong performance of its strategic brands and jump in exports to CIS countries. The results for the relevant period under review are on a merged basis with RPR (Rhone Poulenc Rorer) and hence not exactly comparable on a like to like basis with the previous year numbers.

(Rs m) 3QFY02 3QFY03 % Change 9mFY02 9mFY03 % Change
Net Sales 1,412 1,592 12.7% 3,802 4,516 18.8%
Other Income 26 31 19.2% 81 72 -11.1%
Expenditure 1,141 1,328 16.4% 3,097 3,810 23.0%
Operating Profit (EBDIT) 271 264 -2.6% 705 706 0.1%
Operating Profit Margin (%) 19.2% 16.6%   18.5% 15.6%  
Interest 4 1 -75.0% 15 4 -73.3%
Depreciation 38 38 0.0% 113 112 -0.9%
Profit before Tax 255 256 0.4% 658 662 0.6%
Extraordinary Expenses (VRS) (39) (5) - 31 (4) -
Tax 64 85 32.8% 213 215 0.9%
Profit after Tax/(Loss) 152 166 9.2% 476 443 -6.9%
Net profit margin (%) 10.8% 10.4%   12.5% 9.8%  
No. of Shares (eoy) (m) 23 23   23 23  
Diluted Earnings per share* 26.4 28.9   27.6 25.7  
P/E (at current price)   11.1     12.5  
(*- annualised)            

Domestic sales have grown by 9% from Rs 1.2 bn to Rs 1.3 bn including Rs 96 m from merger of RPR business. The performance has been on the back of strong growth in strategic products such as cardace (20% - cardiovascular), Amaryl (34% - anti-diabetes) and Targocid (29% - anti-infective). In addition, Clexane, acquired from RPR grew by a strong 41% during the quarter. Formulations exports sales (mainly to CIS countries) have recorded a growth of more than 20%.The company’s Ankleshwar unit is being used by the parent as a sourcing base for bulk drugs like Ramipril and Articaine. Further, the company has indicated that the parent has initiated steps to import Daonil formulations (a leading product in anti-diabetic segment) from India. Exports currently account for about 20% of the company’s revenues with Russia and CIS countries accounting for about 85% of the total export pie.

Despite strong sales growth, operating margins have been playing a spoilsport. Operating margins dropped from 19.2% in 3QFY02 to 16.6% this September quarter. Though the company's products enjoy a strong brand equity, it faces stiff competition from generic products. Raw material consumption to sales ratio indicates a drop in realisations for the company's products. Further, operating margins have also been affected on account of front loading of marketing expenses for products (Lantus and Actonel) expected to be launched in the next year. The company has stated that they expect these product promotion expenses to decline in the coming quarters.

Cost break-up
(Rs m) 3QFY02 3QFY03 % Change 9mFY02 9mFY03 % Change
Raw material 744 886 19.1% 1,949 2,425 24.4%
Staff cost 114 119 4.4% 329 383 16.4%
Others 283 323 14.1% 819 1,002 22.3%
Total Expenditure 1,141 1,328 16.4% 3,097 3,810 23.0%

At the current market price of Rs 320, the stock trades at 9.7x our expected earnings for FY03. On the back of the support extended by the parent, Aventis has transformed itself from a company catering mainly to the anti-infectives and pain management segments to a company with a strong and focused portfolio of products for the chronic and critical-care therapeutic segments. The strategic brands continue to grow at healthy growth rates and this is expected to offset the impact of the laggards in its folio. This portfolio bias is expected to continue in the foreseeable future as well. Notwithstanding some unclarity on the impact of the DPCO order, valuations of the company are attractive on a peer comparision basis.

Equitymaster requests your view! Post a comment on "Aventis Pharma: OPM disappointment continues…". Click here!


More Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

My View on ITC (Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

PSU Banks Will Move Up Again (Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

One of the Best Investment Opportunities in the Market Right Now (Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

Why India's Drone Revolution is a 4x Profit Opportunity (Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Oct 29, 2020 (Close)


  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks